Summary A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m 2 /day or 150 mg/m 2 /day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m 2 /day or 125 mg/m 2 /day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3] ) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity. © 2000 Cancer Research Campaign Keywords: malignant glioma; temozolomide; procarbazine; glioblastoma multiforme other refractory cancers (Newlands et al, 1992 O'Reilly et al, 1993; Bleehen et al, 1995; Bower et al, 1997) .
This multicentre phase II study in patients with GBM at first relapse was prompted by the activity of TMZ in recurrent or progressive high-grade glioma and the need for new single-agent treatments with improved efficacy, safety and health-related quality of life (HRQL). The primary objectives were to evaluate the progression-free survival (PFS) at 6 months and safety of TMZ and the reference agent, procarbazine (PCB). PCB is one of the few orally administered therapeutic options available to patients with high-grade gliomas, particularly those who fail radiation and nitrosourea therapy (Kumar et al, 1974; Rodriguez et al, 1989; Newton et al, 1990) . The secondary objectives were to evaluate the effect of TMZ on overall survival, HRQL and response rate.
PATIENTS AND METHODS

Patients
Eligible patients were ≥18 years old, had histologically proven supratentorial GBM or gliosarcoma and unequivocal evidence of tumour recurrence or progression at first relapse by gadolinium magnetic resonance imaging (Gd-MRI) or by contrast-enhanced computerized tomography (CT) scanning after radiation therapy for initial disease. Patients could have had one course of chemotherapy that must have contained a nitrosourea and were required to have a Karnofsky performance status (KPS) of ≥70 and a life expectancy of ≥12 weeks at study entry.
Patients excluded had evidence of significant renal, hepatic or bone marrow impairment (i.e. blood urea nitrogen and creatinine <1.5 times the upper limit of normal; total and direct serum bilirubin <1.5 times the upper limit of normal; absolute neutrophil count [ANC] ≥1500/µl; platelet count >100 000/µl; and haemoglobin >10 g/dl). Other exclusion criteria were >1 prior chemotherapy regimen; history of previous chemotherapy with single-agent PCB or dacarbazine; a regimen of chemotherapy (excluding vincristine, nitrosourea or mitomycin C) within 4 weeks before study drug administration; vincristine within 2 weeks before study drug administration; nitrosourea or mitomycin C within 6 weeks before study drug administration or a history of PCB-induced rash; previous interstitial radiotherapy or stereotactic radiosurgery; pregnancy; breast feeding. Women of childbearing potential had to be using adequate contraceptive precautions. Patients experiencing toxicities from prior therapy, those with medical conditions (HIV) and those with previous or concurrent solid tumours at other sites (excluding basal cell carcinomas) were also excluded.
Study design and drug administration
The protocol was approved by the institutional review board or independent ethics committee of each investigative facility and conducted according to the Declaration of Helsinki and its amendments. Patients gave informed consent before entering the study. A blinded centralized review of neuropathology and neuroradiology was performed. Eligibility was determined by blinded centralized review of at least one histologic specimen from each surgical procedure. GBM was classified according to the Burger and Nelson system McComb and Barger, 1985) .
Monthly performance and clinical evaluation, neurologic examinations, and quality-of-life measurements (questionnaire) were done. Tumour was evaluated every 2 months with Gd-MRI or contrast-enhanced CT scan. Image-based evidence of progression is detectable before clinical deterioration and PFS was determined by image-based progression on Gd-MRI scans, considering all neurologic and clinical data indicative of disease progression. Comprehensive evaluation of neurologic status was performed at study visits comparing signs and symptoms from previous examination. Grading was definitely better (+2); possibly better (+1); unchanged (0); possibly worse (-1); or definitely worse (-2).
Baseline Gd-MRI brain scan must have documented evaluable (measurable or nonmeasurable) residual disease <14 days before study drug administration. Patients were required to be on stable doses of steroids for ≥7 days before the Gd-MRI scan. A baseline Gd-MRI scan was performed within 72 h or 8 to 12 weeks after surgical resection in patients undergoing surgery at first relapse. 
TMZ dosing
Retreatment criteria
If the ANC was ≥2000/µl and the platelet count was ≥125 000/µl, repeat cycles could be administered to a maximum dose of TMZ 200 mg/m 2 /day or PCB 220 mg/m 2 /day. In patients with nadir ANC of 500-999 mm 3 and nadir platelet count of 25,000-49,000 mm 3 , TMZ was reduced to the next lower dosage level (150 mg/m 2 /day or 100 mg/m 2 /day), and PCB dose was reduced by 25% from that of the previous cycle. In patients with nadir ANC of <500 mm 3 and nadir platelet count of <25 000 mm 3 , TMZ was reduced to the next lower dosage level, and PCB was reduced by 50% from that of the previous cycle. For grades 3 and 4 nonhaematologic toxicity, TMZ was reduced by two dosage levels, and PCB was reduced by 50% from that of the previous cycle. Patients continued treatment until unacceptable toxicity developed, disease progressed or 2-year treatment was completed.
Other medications
Patients continued on the lowest steroid dosage necessary for neurologic stability. Colony-stimulating factors were used only in cases of grade 4 neutropenia, when granulocyte colonystimulating factor was permitted.
Response determination
A complete response (CR) was the disappearance of all enhancing tumour on consecutive MRI scans >1 month apart; discontinuation of steroids (except for physiologic doses that may have been Temozolomide vs. procarbazine for relapse of glioblastoma 589 required after prolonged therapy); and stable or improved neurologic status. Partial response (PR) was defined as ≥50% reduction in the sum of the products of the largest perpendicular diameters of contrast enhancement for all measurable lesions or an assessment of 'definitely better' for all nonmeasurable lesions on consecutive MRI scans at least 1 month apart; stable steroid use for 7 days before each scan (at dosage ≤ than had been administered at the time of the previous scan); neurologic status stable or improved. Progressive disease was a ≥25% increase in size of the product of the largest perpendicular diameters of contrast enhancement for any measurable lesions or an assessment of 'definitely worse' for any nonmeasurable lesions or any new tumour on MRI scans. All other situations were considered stable disease (SD).
Adverse drug-mediated events
Adverse events (AEs) were tabulated according to treatment group. Treatment-emergent AEs were those beginning during or within 30 days after the end of treatment or that began before and worsened during treatment, regardless of any relationship to treatment. If CTC criteria were not defined for a parameter, the following grading scale was used: 0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = life-threatening. Abnormal laboratory values were recorded as AEs if they resulted in hospitalisation, transfusion of blood products or discontinuation of therapy. Worsening neurologic deficit was considered as a physical finding associated with neurologic examination rather than an AE. Osoba et al, 1997) and the Brain Cancer Module 20 (BCM20) (Osoba et al, 1996) questionnaires were used to measure HRQL. Questionnaires were administered on day 1 of cycle 1 and at every visit throughout the study. Seven HRQL domains were selected a priori as most clinically relevant to patients with brain cancer: role, social functioning and global quality of life (from the EORTC-QLQ-C30 [+3]) and visual disorder, motor dysfunction, communication deficit and drowsiness (from the BCM20).
HRQL
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30 [+3])
HRQL domains were scored according to EORTC instructions (Fayers et al, 1995) . Tests of statistical significance were not applied. Meaning of changes in HRQL scores was addressed by the method of Osoba et al (1998) . A 10-unit change on a 0-100 scale was deemed significant if it lasted for at least 8 weeks (Jaeschke et al, 1989; Juniper et al, 1994; King, 1996; Ware et al, 1998) . Changes in HRQL scores from baseline were calculated for patients at the same time points as HRQL completion. Proportions of patients achieving an HRQL response (i.e. a 10-point improvement from baseline in a domain for at least 2 consecutive months) were calculated for each group.
Statistical methods
The primary objective was estimation of PFS at 6 months in the intent-to-treat (ITT) population. With 100 patients per group, assuming that the true 6-month PFS rate for TMZ was 20%, the 95% confidence interval (CI) would range from 12.2-27.8%. This assured with confidence that the lower boundary of the 95% CI for the 6-month PFS rate for TMZ would remain higher than 10%, which was assumed to be the threshold of effectiveness.
A log-rank test used retrospectively determined whether meaningful differences were detectable between the two groups. With only progressive disease and death as events, PFS was measured from the start date of treatment to an event date or the last evaluation. Overall survival was measured from the start date of treatment to the date of death or the last evaluation. The product-limit method (Kaplan-Meier) was used to estimate PFS and overall survival. A Cox regression model was used to assess influence of baseline characteristics on the effect of treatment for PFS and overall survival. Subgroup analyses for PFS and overall survival were done according to prognostic variables in the Cox model.
RESULTS
Patient characteristics
Between January 5, 1995, and October 28, 1997, 225 patients were randomised and became the ITT population. Five patients (TMZ, n = 2; PCB, n = 3) were randomized but not treated. Fifteen (13%) TMZ patients and 31 (27%) PCB patients discontinued the study for the following reasons other than disease progression: AEs (TMZ, 3%; PCB, 10%); death (TMZ, 3%; PCB, 5%); noncompliance with either dosing or visit schedule (TMZ, 0%; PCB, 4%); failure to meet protocol eligibility (no treatment) (TMZ, 2%; PCB, 1%); completed treatment (TMZ, 2%; PCB, 1%) or did not wish to continue (TMZ, 4%; PCB, 4%). Histologic review indicated that tumours in 102/112 (91%) TMZ-treated patients and 108/113 (96%) PCB-treated patients were classified correctly as GBM or gliosarcoma. Most patients excluded after reclassification were judged to have anaplastic astrocytoma (7) or anaplastic oligoastrocytoma (3). Specimens for two patients were not reviewed, and one sample was inadequate for review. Baseline and disease characteristics were similar between treatment groups (P ≥ 0.19) ( Table 1) . Median time from the end of radiation therapy to first relapse and median time from initial diagnosis to first relapse were shorter for TMZ-treated patients, but Cox regression analysis revealed that these differences did not affect the overall inferences of the study.
Six-month PFS
For TMZ patients, the 6-month PFS rate was 21% (95% CI, 13-29%), compared with 8% for PCB (95% CI, 3-14%; hazard ratio, n = 1.54; P = 0.008). The 21% 6-month PFS for TMZ met the protocol objective. Respective median PFS was 12.4 weeks for TMZ patients and 8.32 weeks for PCB patients. The overall progression-free interval also favoured TMZ (P = 0.0063) with a hazard ratio of 1.47 (95% CI, 1.11-1.95%) (Figure 1 ). The differences in PFS rate appeared early and were maintained for several months. Results in the subgroup with eligible histology were similar to those reported for the ITT population. In the eligible population, the 6-month PFS rate was 19% (95% CI, 11-27%), compared with 9% for PCB (95% CI, 3-14%) The overall progression-free interval also favoured TMZ (P = 0.0063) in the eligible population with a hazard ratio of 1.37. Analysis of data from time of randomisation showed similar results, with a 6-month PFS rate of 21% (95% CI, 13-29%), compared with 9% for PCB (95% CI, 4-15%; P = 0.016).
Overall survival
The median overall survival with TMZ was 1.5 months longer than that with PCB, but this difference did not reach statistical significance (P = 0.330). At 6 months, survival of the TMZtreated patients was 60% (95% CI, 51-70%) compared with 44% in PCB-treated patients (95% CI, 35-53%; hazard ratio = 1.44; P = 0.019). The overall survival advantage for TMZ appeared at 4-6 months and persisted to at least 8 months (Figure 2 ). Analysis from time of randomisation showed similar results in median overall survival.
Prognostic factors and subgroup analyses
Multivariate analysis of baseline characteristics indicated that PFS was related to baseline KPS (P = 0.0107), and overall survival was related to baseline KPS (P = 0.0024) and age (P = 0.0359).
Patients were stratified by age (>50 or ≤50 years), time from initial diagnosis to first relapse (>8 or ≤8 months), time from end of radiation therapy at initial diagnosis to first relapse (>6 or ≤6 months) and baseline KPS (>80 or ≤80). Analyses of these subgroups demonstrated a consistent advantage for TMZ over PCB on PFS and overall survival regardless of the subgroup; the hazard ratio always exceeded 1.
Objective responses
According to the central reviewer's assessment of objective response, a PR occurred in 6/112 (5.4%) TMZ patients and in 6/113 (5.3%) PCB patients. SD occurred in 45/112 (40.2%) TMZ patients and 31/113 (27.4%) PCB patients. Overall response rates (PR + SD) of 51/112 (45.6%) in the TMZ group were significantly higher than those of 37/113 (32.7%) in PCB group (P = 0.049).
HRQL assessment HRQL scores were available at baseline and postbaseline for 179/220 (81.4%) treated patients. Regardless of the treatment, HRQL scores were maintained at baseline levels prior to disease progression but then decreased substantially at the time of disease progression in six of the seven domains considered most clinically relevant to patients (data not shown). Across all seven domains, the proportions of patients achieving an HRQL response were consistently higher for TMZ than they were for PCB (Figure 3) .
Toxicity
Safety was assessed in the ITT population. Five patients (TMZ, n = 2; PCB, n = 3) who did not receive at least one dose of study medication were excluded from the analysis. A total of 110 TMZtreated patients received 484 cycles of TMZ, and 110 PCB-treated patients received 167 cycles. Most PCB recipients were not treated beyond cycle 1. By the end of week 12, 62/110 (56%) TMZ patients and 36/110 (30%) PCB patients remained in the study, others dropping out primarily for disease progression or toxicity. TMZ and PCB were generally well tolerated, with similar incidence of AEs in both groups ( Table 2 ). The incidence of any AE was 77% in the TMZ group and 76% in the PCB group. As shown in Table 2 , the incidence of grade 3 or 4 treatment-related AEs was less with TMZ (18%) than with PCB (25%). Serious AEs were reported for 169 patients (TMZ, n = 87; PCB, n = 82), primarily for hospitalizations due to disease progression.
TMZ-associated myelosuppression was predictable and reversible with no evidence of cumulative myelotoxicity. Nadir platelet counts or ANCs typically occurred around days 21-28 and recovered generally within 2 weeks. Most frequent AEs with TMZ were nausea (42%), vomiting (35%) and fatigue (30%). Nausea and vomiting were mild to moderate in most cases and were either self-limiting or controlled with antiemetics. Most common CTC grade 3 or 4 toxicities were thrombocytopenia (7%), neutropenia (4%), fatigue (3%), vomiting (3%) and nausea (3%) in a small number of patients in both treatment groups.
DISCUSSION
This large trial involving 255 patients demonstrates the efficacy and safety of TMZ in the treatment of patients with recurrent GBM. This confirms the results of several phase II studies of TMZ in high-grade gliomas (Newlands et al, 1992 O'Reilly et al, 1993; Bower et al, 1997) . Although the median time from initial diagnosis to first relapse as well as the median time from the end of radiation therapy to first relapse was shorter for TMZ recipients than for PCB, a Cox regression analysis showed that these differences did not affect study outcome.
To ensure an objective index of efficacy, Gd-MRI and a mandatory central review were used to evaluate response. Because steroid therapy can produce changes in imaging studies of central nervous system malignancies, a stable dose of steroids before the initial Gd-MRI scan was required; overall response criteria specified that use of steroids should be stable for ≥7 days before the investigator's assessment. Patients adhered to mandated schedules of medical imaging and neurologic examination, and protocol variations were minimal. Oral PCB has demonstrated activity in relapsing malignant gliomas. As the reference agent, PCB verified that objective end points could be seen within the definition of the protocol and permitted comparison of end points. The study size was designed to demonstrate equivalent efficacy between the two drugs. Overall response CPR+SD seen in response to PCB in this study (32.7%) were similar to that found by Rodriguez et al 1989) , but less than that reported by Newton et al (1990) . Comparisons between studies are difficult because of differences in pathologic evaluation of tumours and in the modalities used to measure disease progression.
PFS at 6 months, the primary end point of the protocol, was significantly longer with TMZ than with PCB (21% vs. 8%); overall PFS was also significantly longer for TMZ than for PCB. The difference in PFS in favour of TMZ was observed as early as 1 month after randomisation and was maintained for several months. Although the gain in PFS for TMZ patients did reflect longer overall survival, it did not translate into a significant gain in overall survival. PFS is a reliable and measurable end point when appropriate imaging modalities are used for tumour evaluation and is thus a clinically significant end point. Malignant gliomas are progressive and ultimately fatal tumours; treatment maintaining HRQL and useful survival for months is an important benefit. PFS is also not influenced by subsequent therapies that may follow progression.
Progressive, recurrent GBM causes deterioration of the patient's neurologic status and HRQL. A primary therapy goal in this incurable malignancy is symptom palliation and improvement or maintenance of HRQL. This study demonstrates that disease progression is associated with HRQL deterioration and delaying disease progression provides meaningful maintenance of HRQL to patients with brain tumours. Some of the differences in HRQL response between TMZ and PCB may have been related to the dosing of TMZ over 5 days as compared with PCB, which was dosed over a 28-day period.
Temozolomide has an acceptable safety profile in patients with GBM. Since most PCB recipients were not treated beyond cycle 1, patients received TMZ for a greater number of cycles. The number of patients reporting at least one treatment-related AE was similar for TMZ (77%) and PCB (76%), even though 90% of TMZ patients received more than one cycle of treatment, compared with only 33% of those treated with PCB. To provide balance, AEs were also examined for the first 56 days of treatment (i.e. one complete cycle for PCB). During this period, more PCB patients (21%) reported severe or life-threatening treatment-related AEs than TMZ patients (15%). Only three TMZ patients dropped out because of AEs compared with 11 PCB patients. Although myelosuppression is a well-established dose-limiting side effect of treatment with all alkylating agents, it occurred in only a small number of TMZ recipients. When neutropenia and thrombocytopenia developed, they usually occurred in the first few treatment cycles, resolved with a one-level reduction in dosage and were not cumulative.
This study demonstrates the safety and efficacy of TMZ in recurrent GBM. TMZ is associated with an improvement in the patient's HRQL. The antitumour activity and predictability of TMZ may prove valuable in patients with anaplastic astrocytomas and in trials of patients with metastatic malignant melanoma and other therapy-resistant tumours. Further benefit is anticipated on combination of TMZ with agents such as the nitrosoureas, taxanes, topoisomerase inhibitors and biologic-response modifiers and in alternate dosing regimens (e.g. continuous-dosing studies).
